3results about How to "Strong secretory ability" patented technology

The invention belongs to the technical field of biology, and particularly relates to an immune engineering cell for expressing a discontinuous truncated functional region of GM-CSF and application. The invention firstly provides a CAR-NK cell for expressing a discontinuous truncated functional region of GM-CSF, and the CAR-NK cell expresses a novel chimeric antigen receptor structure; the novel chimeric antigen receptor structure comprises a discontinuous truncated functional domain fragment of a GM-CSF protein and a chimeric antigen receptor; the non-continuous truncated functional domain fragment of the GM-CSF protein comprises an A helix fragment, a C helix fragment and an exon 2 fragment. The invention also provides a CAR-T cell for expressing the discontinuous truncated functional region of the GM-CSF as well.

The invention belongs to the technical field of bioactive peptides, and particularly relates to a pork liver by-product polypeptide as well as a preparation method and application thereof. The preparation method of the pork liver by-product polypeptide comprises the following specific steps: S1, adding pork liver into a phosphate buffer solution, crushing, centrifuging, collecting supernate, dialyzing the supernate, and freeze-drying to obtain pork liver protein; s2, dissolving the pork liver protein in deionized water, incubating, adjusting the pH value, adding protease for enzymolysis, deactivating enzyme, cooling, centrifuging, taking supernate, and freeze-drying, so as to obtain the pork liver by-product polypeptide. Compared with an existing method, the method is easy to operate and high in practicability, and the prepared pork liver by-product polypeptide has high anti-inflammatory activity and can regulate secretion of inflammatory factors.

This invention discloses the application of induced pluripotent stem cell (EPC) derived from induced pluripotent stem cell differentiation in the preparation of stroke therapeutic agents. Through intravenous injection of EPCs into an animal model of stroke, this invention demonstrates that this method can treat stroke by inhibiting atherosclerosis, reducing cerebral infarction levels, promoting angiogenesis in lesioned brain tissue, improving inflammatory responses in lesioned brain tissue, and repairing nerve damage and brain injury. The above research results of this invention provide a new treatment method for stroke in clinical practice.